aBLA Filing Intelligence & Biosimilar Opportunity

Bimzelx

Bimekizumab

Immunomodulators

Injection

Bimzelx is a subcutaneous injection used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis), and hidradenitis suppurativa. It targets and blocks IL‑17A and IL‑17F cytokines to reduce inflammation and skin/joint symptoms.

Approval Date

17-Oct-23

Data Exclusivity Expiry

17-Oct-27

Market Exclusivity Expiry

17-Oct-35

Commercial snapshot

Market performance & projections

Revenue ($M)

2513

CAGR (%)

0.2725

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

3581

2027

4699

2028

5723

2029

6589

2030

7330

2031

7960

2032

8384

Molecule profile

Details & specifications

Molecule

Bimekizumab

Innovator

UCB INC

Dosage Form

Injection

Strength

160 mg/mL

Therapeutic Category

Immunomodulators

Usage

To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.